ELCC 2016 News: Updates from CheckMate 063 and 017 Trials Confirm Nivolumab Efficacy in Patients with Advanced Platinum-Refractory Squamous NSCLC


“The baseline serum cytokine levels of platinum pretreated patients with advanced squamous non-small cell lung cancer (NSCLC) altered the efficacy of immunotherapy with nivolumab, a fully human IgG4 antibody inhibiting the programmed death-1 (PD-1) immune checkpoint.

“Updated findings from the phase II CheckMate 063 trial of nivolumab and phase III CheckMate 017 trial of nivolumab versus docetaxel in patients with advanced platinum-refractory squamous NSCLC were submitted by Dr Hervé Lena, Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Rennes, France and colleagues, including Suresh Ramalingam who presented the results at the European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, 13 to 16 April, 2016.”

Go to full article.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.